While we are positive about making Phase 2 of Oncode a reality, we are not there yet. We are currently finalizing the details of our proposed strategy and budget in close collaboration with our funders: KWF, the ministries of VWS, OCW and EZK, ZonMw and Health~Holland.

As a part of moving into Phase 2, Oncode Institute has been assessed by our International Advisory Board and International Review Committee. As part of the institute’s assessment, a large part of our 61 Oncode Investigator (OI) team has been evaluated. All senior OIs, and junior OIs who started in 2017 were evaluated by external experts within an extensive review process. The evaluation focused on the scientific excellence and contribution to Oncode’s goals (e.g. valorization, collaboration and community activities) of individual OIs.

Based on advice from the International Advisory Board and the International Review Committee, the final selection of OIs to continue into phase 2 was made by Oncode’s Managing Board (MB). The MB focused on assembling an excellent, impactful and diverse team and today we have informed our current OIs of the outcome of the procedure. Contingent on reaching an agreement with our funders, we will continue with 52 OIs into phase 2 of Oncode. The composition of our OI team is listed in this overview.

We have reserved funding for a new recruitment round, through which the group of OIs will be expanded as of January 2024. The thematic focus and exact conditions are still to be determined, but the selection of new OIs will be based on scientific excellence, a collaborative spirit and complementing the Oncode research portfolio.

We would like to thank all OIs and researchers who contributed to phase 1 of Oncode for their hard work and the value they added to our community and beyond. More detailed information on the team and our new strategy will be available once we have reached final agreements with our funders.